Drugs / DZ-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04970992 | Aug 2021 → Nov 2024 | cancer, lymphoma | Da Zen Theranostics Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07344220 | Jan 2026 → Nov 2028 expected | pancreatic adenocarcinoma | Hoag Memorial Hospital Presbyterian | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DZ-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04970992 ↗ |
| Route | Intravenous | “administered as a weekly intravenous (IV) infusion” NCT04970992 ↗ |